Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs

Marburg virus (MARV) is a virus of high human consequence with a case fatality rate of 24–88%. The global health and national security risks posed by Marburg virus disease (MVD) underscore the compelling need for a prophylactic vaccine, but no candidate has yet reached regulatory approval. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Finch, Courtney L., King, Thomas H., Alfson, Kendra J., Albanese, Katie A., Smith, Julianne N. P., Smock, Paul, Jakubik, Jocelyn, Goez-Gazi, Yenny, Gazi, Michal, Dutton, John W., Clemmons, Elizabeth A., Mattix, Marc E., Carrion, Ricardo, Rudge, Thomas, Ridenour, Alex, Woodin, Sovann F., Hunegnaw, Ruth, Sullivan, Nancy J., Xu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694189/
https://www.ncbi.nlm.nih.gov/pubmed/36423030
http://dx.doi.org/10.3390/vaccines10111935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694189/
https://www.ncbi.nlm.nih.gov/pubmed/36423030
http://dx.doi.org/10.3390/vaccines10111935

Ejemplares similares